Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kane BiotechKNBIF -0.45% 3-Year Revenue Growth Rate is 44.20% as of Mar. 2026, which is 602% above its 10-year median of 6.30. The stock has 6 warning signs investors should review. Among 768 Biotechnology companies, Kane Biotech ranks better than 82.55% on this metric.
During the past 12 months, Kane Biotech's average Revenue per Share Growth Rate was -100.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 44.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -18.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -9.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Kane Biotech was 51.80% per year. The lowest was -63.80% per year. And the median was 6.30% per year.
Kane Biotech (OTCPK:KNBIF) 3-Year Revenue Growth Rate Explanation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Kane Biotech 3-Year Revenue Growth Rate Related Terms
KNBIF vs VRTX, REGN, RVMD: 3-Year Revenue Growth Rate Comparison
For the Biotechnology subindustry, Kane Biotech's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kane Biotech 3-Year Revenue Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kane Biotech's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Kane Biotech's 3-Year Revenue Growth Rate falls into.
Kane Biotech 3-Year Revenue Growth Rate Calculation
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
What does a 3-Year Revenue Growth Rate of 44.20% mean?
Kane Biotech (KNBIF) has a 3-Year Revenue Growth Rate of 44.20% as of Mar. 2026. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Kane Biotech and its competitors. This is 602% above median its historical median of 6.30. According to the industry distribution chart, Kane Biotech ranks #134 out of 768 companies in the Biotechnology industry, placing it in the top 17.4%.
Is Kane Biotech's 3-Year Revenue Growth Rate too high?
Kane Biotech's current 3-Year Revenue Growth Rate of 44.20% is 602% above median its 10-year median of 6.30. The Biotechnology industry median 3-Year Revenue Growth Rate is 2.95. Kane Biotech's value of 44.20% is 1398.3% above this industry median. Based on the distribution chart, Kane Biotech ranks #134 out of 768 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Kane Biotech's 3-Year Revenue Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kane Biotech ranks #134 out of 768 companies for 3-Year Revenue Growth Rate. This places Kane Biotech in the top 17% of its industry — outperforming the majority of peers. The industry median 3-Year Revenue Growth Rate is 2.95. Kane Biotech's value of 44.20% is 1398.3% above this benchmark. While the company's 10-year median is 6.30 vs. the industry median of 2.95, Kane Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Biotechnology company?
The median 3-Year Revenue Growth Rate among Biotechnology companies is 2.95, based on 768 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kane Biotech's current 3-Year Revenue Growth Rate of 44.20% is 1398.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Kane Biotech and its competitors. For the Biotechnology industry, the median 3-Year Revenue Growth Rate is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kane Biotech's current 3-Year Revenue Growth Rate is 44.20%, which is 602% above median its own 10-year median of 6.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kane Biotech stock overvalued right now?
Kane Biotech (KNBIF) has a current 3-Year Revenue Growth Rate of 44.20%. The current 3-Year Revenue Growth Rate is 44.20%, which is 602% above median its 10-year median of 6.30 and 1398.3% above the Biotechnology industry median of 2.95. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For Kane Biotech (KNBIF), the current 3-Year Revenue Growth Rate is 44.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNBIF has been successfully added to your 
